Myelosuppression After Frontline Fludarabine, Cyclophosphamide, and Rituximab in Patients With Chronic Lymphocytic Leukemia: Analysis of Persistent and New-Onset Cytopenia

BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Strati, Paolo, Wierda, William, Burger, Jan, Ferrajoli, Alessandra, Tam, Constantine, Lerner, Susan, Keating, Michael J., O’Brien, Susan
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535913/
https://ncbi.nlm.nih.gov/pubmed/23943357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28318
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky